OXFORD and LONDON, UK I December 18, 2020 I Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it is collaborating with Prof. Robin Shattock, a leading infectious disease and vaccine expert, and his group at Imperial College London (“Imperial”), to develop RNA vaccines, including against SARS-CoV-2, that are stable at ambient temperatures and up to 40o Celsius (104o Fahrenheit).
The ability to create such vaccines could minimize or eliminate the cold chain requirements for global deployment and mass vaccination programmes with RNA-based vaccines.
The collaboration will investigate the potential of combining Enesi’s ImplaVax® technology for the creation of thermostable, solid dose vaccines with RNA vaccines based on Imperial’s self-amplifying RNA (saRNA) technology and novel Polyplex DNA/RNA stabilisation technologies. ImplaVax® technology enables the development of solid dose vaccines of a fixed (unit) dose that are designed to be delivered using a needle-free device into the dermal layer of the skin and with minimal administrator training.
An early phase of the collaboration – to assess the feasibility of creating a thermostable and immunogenic, solid dose DNA vaccine employing Enesi’ ImplaVax® and Imperial’s Polyplex technologies – has been completed successfully. Based on these results, Enesi and Imperial are advancing their collaboration into a new phase to develop and evaluate the effectiveness of RNA vaccines using saRNA, Polyplex and ImplaVax technologies.
The successful production of a solid dose RNA vaccine, and demonstration of an appropriate immune response could lead to a further partnership to develop at pace an ImplaVax® version of Imperial’s RNA vaccine against SARS-CoV-2, which is based on the virus’ spike protein and is being investigated in a Phase I/II trial in over 400 healthy subjects.
David Hipkiss, Enesi Pharma CEO, said:
“Vaccines have been front-page news in recent months with astonishing progress being made since the outbreak of the COVID-19 pandemic. This global awareness has highlighted not only the potential of novel vaccine design and development technologies such as mRNA and adenoviral vectors but also the challenges of mass vaccination and in some cases the need for extreme ultra-cold chains for the distribution and storage of products, and the highly complex challenge of deployment and administration that follows.
“We believe that our ImplaVax technology may hold the key to solving these issues and we have already established in-vivo proof of concept with multiple vaccine formats currently being used and in development for a wide range of infectious diseases, including those being use for COVID-19.
“Currently hundreds of millions of doses need to be produced, stored and transported in a cold chain, and then administered using a needle and syringe and diluents which adds cost, complexity and risk requiring a high degree of skill for administration.
“We are particularly excited with the progress in our collaboration with Prof. Shattock and his group at Imperial given the breakthroughs made with mRNA vaccines. We are hopeful that our collaboration combining our next-generation technologies, will solve these challenges for the benefit of the global population and facilitate the administration of mRNA vaccines anywhere, any time and by anyone independent of geography or socioeconomic circumstance.”
Prof. Robin Shattock, Head of Mucosal Infection and Immunity within the Department of Infectious Disease at Imperial College London said:
“Our innovative saRNA technology used in our COVID-19 vaccine holds great potential in the fight against this disease, and many others. However there remains a number of challenges to address to be able to provide broad coverage against the virus throughout the world population, including in terms of storing, shipping and administering a vaccine at such an unprecedented scale. As we make good progress towards evaluating the efficacy of our vaccine, it is critical that in parallel we explore ways to potentially address those challenges, particularly in terms of minimising and ideally eliminating cold chain supply and the use of needle and syringes, which could be an important barrier to rapid deployment of vaccination efforts globally.”
About Prof. Shattock and his group
Robin Shattock is a Professor of Mucosal Infection and Immunity in the Department of Infectious Diseases at Imperial College, London. Prof Shattock has been leading Imperial Colleges program to develop a self-amplifying RNA (saRNA) vaccine against SARS CoV2, the virus that causes COVID-19. This innovative technology has the potential to induce potent immune responses using very low doses of the vaccine. He has developed an active formulation that consists of a biodegradable polyplex (charged polymer) that enhances the uptake and expression of saRNA that is ideally suited for development of a solid dosage approach developed by Enesi Pharma.
The wider focus of his research is the investigation of the mechanisms of mucosal infection and development of novel preventative strategies. His group has a strong research program on the mucosal immune responses to infection and vaccination, with active programs on HIV, Ebola, Lassa fever, Marburg viruses and Chlamydia. Prof Shattock has secured funding from the MRC-UK, EPSRC, CEPI and European Commission. He is the scientific director of the European AIDS Vaccine Initiative (EAVI2020) that coordinates a program of EU funded vaccine research across 22 institutions. He directs the Future Vaccines Manufacturing Research Hub at Imperial College. He is the Founder of VaxEquity Ltd an Imperial Spin out focused on the commercialization of saRNA vaccine technology. His is an elected fellow of the Academy of Medical Sciences.
About Imperial College London
Imperial College London is one of the world’s leading universities. The College’s 17,000 students and 8,000 staff are expanding the frontiers of knowledge in science, medicine, engineering and business, and translating their discoveries into benefits for our society.
Imperial is the UK’s most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK’s most innovative university because of its exceptional entrepreneurial culture and ties to industry.
http://www.imperial.ac.uk/
Imperial’s COVID-19 vaccine candidate is based on synthetic genetic code (called self-amplifying RNA) encoding for a spike protein on the surface of the SARS-CoV-2 virus.
https://www.imperial.ac.uk/covid-19-vaccine-trial/
About Enesi Pharma
Enesi Pharma is developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies. These diseases affect millions of people around the world. We work in partnership with global companies, government agencies, leading academic institutions and non-governmental organisations with the goal of making a material and lasting positive impact on global health.
Our award-winning ImplaVax®-enabled vaccination products leverage our innovative unit solid-dose formulation and needle-free delivery technologies and are applicable across all vaccine formats. ImplaVax® products are designed to enhance the immune response and offer significant benefits for patients, care givers, healthcare professionals and payers through enhanced effectiveness, safety, ease of use, reliability and stability, and a strong subject preference over administration using needle and syringe. They can be administered with minimal training and are also rapidly deployable while eliminating the need for cold-chain storage.
Our pipeline targets a range of common and emerging infectious diseases, inflammatory diseases and allergies, and has been established through collaborations with world-class organisations, including BARDA DRIVe*, the Bill & Melinda Gates Foundation, Innovate UK, the University of Oxford, the Walter Reed Army Institute of Research (WRAIR), Sementis and the University of Adelaide. Our recently announced collaboration with Pirbright is one of a number of developing collaborations in animal health.
Enesi’s experienced leadership team has a proven track record in the successful development and commercialisation of innovative products delivering high value outcomes for all stakeholders and is supported by a world-renowned Scientific Advisory Board.
*This project has been funded in whole or in part with US Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, DRIVe, under this contract.
SOURCE: Enesi Pharma
Post Views: 17
OXFORD and LONDON, UK I December 18, 2020 I Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it is collaborating with Prof. Robin Shattock, a leading infectious disease and vaccine expert, and his group at Imperial College London (“Imperial”), to develop RNA vaccines, including against SARS-CoV-2, that are stable at ambient temperatures and up to 40o Celsius (104o Fahrenheit).
The ability to create such vaccines could minimize or eliminate the cold chain requirements for global deployment and mass vaccination programmes with RNA-based vaccines.
The collaboration will investigate the potential of combining Enesi’s ImplaVax® technology for the creation of thermostable, solid dose vaccines with RNA vaccines based on Imperial’s self-amplifying RNA (saRNA) technology and novel Polyplex DNA/RNA stabilisation technologies. ImplaVax® technology enables the development of solid dose vaccines of a fixed (unit) dose that are designed to be delivered using a needle-free device into the dermal layer of the skin and with minimal administrator training.
An early phase of the collaboration – to assess the feasibility of creating a thermostable and immunogenic, solid dose DNA vaccine employing Enesi’ ImplaVax® and Imperial’s Polyplex technologies – has been completed successfully. Based on these results, Enesi and Imperial are advancing their collaboration into a new phase to develop and evaluate the effectiveness of RNA vaccines using saRNA, Polyplex and ImplaVax technologies.
The successful production of a solid dose RNA vaccine, and demonstration of an appropriate immune response could lead to a further partnership to develop at pace an ImplaVax® version of Imperial’s RNA vaccine against SARS-CoV-2, which is based on the virus’ spike protein and is being investigated in a Phase I/II trial in over 400 healthy subjects.
David Hipkiss, Enesi Pharma CEO, said:
“Vaccines have been front-page news in recent months with astonishing progress being made since the outbreak of the COVID-19 pandemic. This global awareness has highlighted not only the potential of novel vaccine design and development technologies such as mRNA and adenoviral vectors but also the challenges of mass vaccination and in some cases the need for extreme ultra-cold chains for the distribution and storage of products, and the highly complex challenge of deployment and administration that follows.
“We believe that our ImplaVax technology may hold the key to solving these issues and we have already established in-vivo proof of concept with multiple vaccine formats currently being used and in development for a wide range of infectious diseases, including those being use for COVID-19.
“Currently hundreds of millions of doses need to be produced, stored and transported in a cold chain, and then administered using a needle and syringe and diluents which adds cost, complexity and risk requiring a high degree of skill for administration.
“We are particularly excited with the progress in our collaboration with Prof. Shattock and his group at Imperial given the breakthroughs made with mRNA vaccines. We are hopeful that our collaboration combining our next-generation technologies, will solve these challenges for the benefit of the global population and facilitate the administration of mRNA vaccines anywhere, any time and by anyone independent of geography or socioeconomic circumstance.”
Prof. Robin Shattock, Head of Mucosal Infection and Immunity within the Department of Infectious Disease at Imperial College London said:
“Our innovative saRNA technology used in our COVID-19 vaccine holds great potential in the fight against this disease, and many others. However there remains a number of challenges to address to be able to provide broad coverage against the virus throughout the world population, including in terms of storing, shipping and administering a vaccine at such an unprecedented scale. As we make good progress towards evaluating the efficacy of our vaccine, it is critical that in parallel we explore ways to potentially address those challenges, particularly in terms of minimising and ideally eliminating cold chain supply and the use of needle and syringes, which could be an important barrier to rapid deployment of vaccination efforts globally.”
About Prof. Shattock and his group
Robin Shattock is a Professor of Mucosal Infection and Immunity in the Department of Infectious Diseases at Imperial College, London. Prof Shattock has been leading Imperial Colleges program to develop a self-amplifying RNA (saRNA) vaccine against SARS CoV2, the virus that causes COVID-19. This innovative technology has the potential to induce potent immune responses using very low doses of the vaccine. He has developed an active formulation that consists of a biodegradable polyplex (charged polymer) that enhances the uptake and expression of saRNA that is ideally suited for development of a solid dosage approach developed by Enesi Pharma.
The wider focus of his research is the investigation of the mechanisms of mucosal infection and development of novel preventative strategies. His group has a strong research program on the mucosal immune responses to infection and vaccination, with active programs on HIV, Ebola, Lassa fever, Marburg viruses and Chlamydia. Prof Shattock has secured funding from the MRC-UK, EPSRC, CEPI and European Commission. He is the scientific director of the European AIDS Vaccine Initiative (EAVI2020) that coordinates a program of EU funded vaccine research across 22 institutions. He directs the Future Vaccines Manufacturing Research Hub at Imperial College. He is the Founder of VaxEquity Ltd an Imperial Spin out focused on the commercialization of saRNA vaccine technology. His is an elected fellow of the Academy of Medical Sciences.
About Imperial College London
Imperial College London is one of the world’s leading universities. The College’s 17,000 students and 8,000 staff are expanding the frontiers of knowledge in science, medicine, engineering and business, and translating their discoveries into benefits for our society.
Imperial is the UK’s most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK’s most innovative university because of its exceptional entrepreneurial culture and ties to industry.
http://www.imperial.ac.uk/
Imperial’s COVID-19 vaccine candidate is based on synthetic genetic code (called self-amplifying RNA) encoding for a spike protein on the surface of the SARS-CoV-2 virus.
https://www.imperial.ac.uk/covid-19-vaccine-trial/
About Enesi Pharma
Enesi Pharma is developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies. These diseases affect millions of people around the world. We work in partnership with global companies, government agencies, leading academic institutions and non-governmental organisations with the goal of making a material and lasting positive impact on global health.
Our award-winning ImplaVax®-enabled vaccination products leverage our innovative unit solid-dose formulation and needle-free delivery technologies and are applicable across all vaccine formats. ImplaVax® products are designed to enhance the immune response and offer significant benefits for patients, care givers, healthcare professionals and payers through enhanced effectiveness, safety, ease of use, reliability and stability, and a strong subject preference over administration using needle and syringe. They can be administered with minimal training and are also rapidly deployable while eliminating the need for cold-chain storage.
Our pipeline targets a range of common and emerging infectious diseases, inflammatory diseases and allergies, and has been established through collaborations with world-class organisations, including BARDA DRIVe*, the Bill & Melinda Gates Foundation, Innovate UK, the University of Oxford, the Walter Reed Army Institute of Research (WRAIR), Sementis and the University of Adelaide. Our recently announced collaboration with Pirbright is one of a number of developing collaborations in animal health.
Enesi’s experienced leadership team has a proven track record in the successful development and commercialisation of innovative products delivering high value outcomes for all stakeholders and is supported by a world-renowned Scientific Advisory Board.
*This project has been funded in whole or in part with US Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, DRIVe, under this contract.
SOURCE: Enesi Pharma
Post Views: 17
